| Business Summary | | Teva
Pharmaceutical
Industries
Ltd.
is
a
fully
integrated
global
pharmaceutical
company
producing
drugs
in
all
major
therapeutic
categories.
In
the
area
of
proprietary
drugs,
Teva
has
focused
on
products
for
central
nervous
system
disorders,
primarily
the
development
of
Teva's
first
globally
marketed
branded
drug,
Copaxone,
a
treatment
for
relapsing-remitting
multiple
sclerosis.
Teva
also
possesses
significant
manufacturing
operations
for
active
pharmaceutical
ingredients
(API).
Teva
Pharmaceuticals
USA,
Inc.,
Teva's
principal
United
States
subsidiary,
is
a
generic
drug
company
in
the
United
States.
Teva
manufactures
137
generic
products
in
210
generic
forms,
which
are
distributed
and
sold
in
the
United
States
together
with
15
additional
generic
products
in
29
dosage
forms
manufactured
by
third
parties.
Teva
manufactures
over
270
generic
products
in
600
dosage
forms,
which
are
sold
primarily
in
the
Netherlands,
the
United
Kingdom
and
Hungary. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Teva
Pharmaceutical
Industries
Ltd.
through
its
subsidiaries
and
associated
companies
develops,
distributes,
produces
and
markets
all
major
theraputic
drugs.
For
the
six
months
ended
6/30/01,
sales
increased
29%
to
$1
billion.
Net
income
before
US
GAAP
totalled
$119.2
million,
up
from
$45.2
million.
Revenues
reflect
the
acquisitions
of
Novopharm
and
increased
sales
of
new
products.
Earnings
also
reflect
higher
margins
due
to
economies
of
scale
and
and
lower
interest
expense. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Meir Heth, 68 | Chairman | Eli Hurvitz, 68 | Pres,
Chief Exec. Officer | Dan Suesskind, 57 | CFO,
Director | Israel Makov, 62 | COO | Haim Benjamin, 61 | VP,
HR |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|